Caxton Associates LP Denali Therapeutics Inc. Transaction History

Caxton Associates LP

  • $2.65 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019
SELL
$17.99 - $24.65 $2.41 Million - $3.3 Million
-134,047 Closed
0 $0
Q4 2018

Feb 14, 2019
BUY
$13.88 - $21.75 $416,400 - $652,500
30,000 Added 28.83%
134,047 $2.77 Million
Q3 2018

Nov 14, 2018
BUY
$12.46 - $21.74 $1.3 Million - $2.26 Million
104,047 New
104,047 $2.26 Million

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Caxton Associates LP Portfolio

Follow Caxton Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Caxton Associates LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email